Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice
✍ Scribed by Leying Zhang; Darya Alizadeh; Michelle Van Handel; Marcin Kortylewski; Hua Yu; Behnam Badie
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 481 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0894-1491
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
As the main effector‐cell population of the central nervous system, microglia (MG) are considered to play an important immunoregulatory function in a number of pathological conditions such as inflammation, trauma, degenerative disease, and brain tumors. Recent studies, however, have suggested that the anti‐neoplastic function of MG may be suppressed in malignant brain tumors. Considering the proposed suppressive role of signal transducers and activators of transcription 3 (Stat3) in antitumor immunity, we evaluated the role of Stat3 inhibition on MG and macrophage (MP) activation and tumor growth in a murine glioma model. N9 MG cells were exposed to GL261 glioma conditioned medium (GL261‐CM) and evaluated for Stat3 activity and cytokine expression. Furthermore, the role of Stat3 inhibition on MG and MP activation was studied both in vitro and in vivo. Finally, the effect of Stat3 inhibition on tumor growth was assessed in intracranial GL261 gliomas. GL261‐CM increased Stat3 activity in N9 cells in vitro and resulted in overexpression of IL‐10 and IL‐6, and downregulation of IL1‐β, a pro‐inflammatory cytokine. Inhibition of Stat3 by CPA‐7 or siRNA reversed glioma‐induced cytokine expression profile in N9 cells. Furthermore, inactivation of Stat3 in intracranial GL261 tumors by siRNA resulted in MG/MP activation and tumor growth inhibition. Glioma‐induced MG and MP suppression may be mediated thorough Stat3. Inhibition of Stat3 function in tumor MG/MP may result in their activation and can potentially be used as an adjunct immunotherapy approach for gliomas. © 2009 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract We characterized the effects of a newly developed signal transducers and activators of transcription 3 (STAT3) inhibitor, LLL12 in multiple myeloma (MM) cells. LLL12 specifically inhibited STAT3 phosphorylation, nuclear localization, DNA binding activity, down‐regulated STAT3 downstream
The effects of a new metalloproteinase inhibitor, BE 16627B [L-N-(N-hydroxy-2-isobutylsuccinynamoyl)-se~l-L-valine, M W 375.21 isolated from microbial cultures, on human tumor cell growth in nude mice were investigated. BEl6627B inhibited metalloproteinases in enzyme assays, as well as gelatinolysis